

*National Voluntary Consensus for Patient Safety Measures 2010 Project*  
**Table of Candidate Consensus Standards - updated October 18, 2010**

Measure ID/ Title	Measure Description	Measure Steward
<b>Healthcare Acquired Infections</b>		
<b># PSM-001-10</b> <b>National Healthcare Safety Network (NHSN) Central line-associated Bloodstream Infection (CLABSI) Outcome Measure</b>	Standardized Infection Ratio (SIR) of CLABSIs among patients in intensive care units (ICUs) and Neonatal Intensive Care Units (NICUs).	Centers for Disease Control and Prevention (CDC)
<b># PSM-002-10</b> <b>National Healthcare Safety Network (NHSN) Surgical Site Infection (SSI) Outcome Measure</b>	Standardized Infection Ratio (SIR) of SSIs among patients who underwent any National Healthcare Safety Network (NHSN) surgical procedure corresponding to the Surgical Care Improvement Program (SCIP) coronary artery bypass graft, other cardiac, colon, hip or knee arthroplasty, abdominal and vaginal hysterectomy, or vascular procedures.	Centers for Disease Control and Prevention (CDC)
<b># PSM-003-10</b> <b>National Healthcare Safety Network (NHSN) Catheter-associated Urinary Tract Infection (CAUTI) Outcome Measure</b>	Standardized Infection Ratio (SIR) of CAUTIs among patients in intensive care units (ICUs), excluding patients in neonatal ICUs (NICUs).	Centers for Disease Control and Prevention (CDC)
<b># PSM-004-10</b> <b>Central Venous Catheter-related Bloodstream Infections (adults)</b> <i>* This measure has been withdrawn.</i>	Number of central venous catheter-related bloodstream infections per 1,000 discharges in cases age 18 years and older	Agency for Healthcare Research and Quality (AHRQ)
<b># PSM-005-10</b> <b>Central Venous Catheter-related Bloodstream Infections (pediatrics)</b> <i>* This measure has been withdrawn.</i>	Number of central venous catheter-related bloodstream infections per 1,000 discharges in cases under age 18 years	Agency for Healthcare Research and Quality (AHRQ)
<b># PSM-006-10</b> <b>Risk Adjusted Surgical Site Infection Outcome Measure</b>	This is a hospital based, risk adjusted, case mix adjusted surgical site infection measure of adults 18 years of age and over.	American College of Surgeons
<b># PSM-007-10</b> <b>Risk Adjusted Urinary Tract Infection Outcome Measure</b>	Risk-adjusted, case mix-adjusted urinary tract infection outcome measure of adults 18+ years	American College of Surgeons

This information is for personal and noncommercial use only. You may not modify, reformat, copy, display, distribute, transmit, publish, license, create derivative works from, transfer or sell any information, products or services obtained from this document.

*National Voluntary Consensus for Patient Safety Measures 2010 Project*  
**Table of Candidate Consensus Standards - updated October 18, 2010**

Measure ID/ Title	Measure Description	Measure Steward
<b># PSM-008-10</b> <b>Surgical Site Infection Rate - Ambulatory Surgery</b> <i>* This measure has been withdrawn.</i>	The measure identifies the percentage of ambulatory surgery admissions developing a post-operative surgical site infection within 30 days after the operation, or within 1 year of the operation if an implant was placed.	ASC Quality Collaboration
<b>Medication Safety</b>		
<b># PSM-009-10</b> <b>Medication Administration Variance</b> <i>* This measure has been withdrawn.</i>	This measure identifies the percentage of ambulatory surgery admissions experiencing a medication administration variance prior to discharge.	ASC Quality Collaboration
<b># PSM-010-10</b> <b>Querying and Counseling about Anti-Epileptic Drug (AED) Side-Effects</b>	Percentage of patient visits for patients with a diagnosis of epilepsy where the patients were queried and counseled about Anti-Epileptic Drug (AED) side-effects and the querying and counseling was documented in the medical record.	© American Academy of Neurology
<b># PSM-017-10</b> <b>Patient(s) with rheumatoid arthritis taking methotrexate, sulfasalazine, or leflunomide that had serum ALT or AST test in last 3 reported months.</b>	This measure identifies individuals with rheumatoid arthritis, 2 years of age or older, taking methotrexate, sulfasalazine, or leflunomide that had a serum ALT/AST test in last 3 months of the report period.	© Ingenix, Inc.
<b># PSM-018-10</b> <b>Patient(s) with rheumatoid arthritis taking methotrexate or sulfasalazine that had a serum creatinine in last 6 reported months.</b>	This measure identifies individuals with rheumatoid arthritis, 2 years of age or older, taking methotrexate or sulfasalazine that had a serum creatinine test in last 6 months of the report period.	© Ingenix, Inc.
<b># PSM-019-10</b> <b>Patient(s) with rheumatoid arthritis taking methotrexate, sulfasalazine, gold, or leflunomide that had a CBC in last 3 reported months.</b>	This measure identifies individuals with rheumatoid arthritis, 2 years of age or older, taking methotrexate, sulfasalazine, gold, or leflunomide that had a CBC test in last 3 months of the report period.	© Ingenix, Inc.
<b># PSM-020-10</b> <b>Patient(s) with inflammatory bowel disease taking methotrexate, azathioprine or mercaptopurine that had serum ALT or AST test in last 6 reported months.</b>	This measure identifies individuals with inflammatory bowel disease, 12 years of age or older, taking methotrexate, azathioprine or mercaptopurine that had a serum ALT/AST test in last 6 months of the report period.	© Ingenix, Inc.

This information is for personal and noncommercial use only. You may not modify, reformat, copy, display, distribute, transmit, publish, license, create derivative works from, transfer or sell any information, products or services obtained from this document.

*National Voluntary Consensus for Patient Safety Measures 2010 Project*  
**Table of Candidate Consensus Standards - updated October 18, 2010**

Measure ID/ Title	Measure Description	Measure Steward
# PSM-021-10 <b>Adult patient(s) with multiple sclerosis taking interferon that had a serum ALT/AST test in last 12 reported months.</b>	This measure identifies adults with multiple sclerosis taking interferon that had at least one serum ALT/AST test in last 12 months of the report period.	© Ingenix, Inc.
# PSM-022-10 <b>Adult patient(s) with multiple sclerosis taking interferon that had a CBC in last 12 reported months.</b>	This measure identifies adults with multiple sclerosis taking interferon that had at least one CBC test in last 12 months of the report period.	© Ingenix, Inc.
# PSM-023-10 <b>Patient(s) with hepatitis C infection taking interferon that had periodic serum ALT monitoring.</b>	This measure identifies hepatitis C virus (HCV) infected persons, 3 years of age or older, taking interferon that had at least two serum tests in last 6 months of the report period.	© Ingenix, Inc.
# PSM-024-10 <b>Patient(s) with hepatitis C infection taking interferon that had periodic CBC with differential monitoring.</b>	This measure identifies hepatitis C virus (HCV) infected persons, 3 years of age or older, taking interferon that had at least two CBC with differential tests in last 6 months of the report period.	© Ingenix, Inc.
# PSM-025-10 <b>Patient(s) with HIV infection taking antiretroviral medications that had a serum ALT or AST test in last 6 reported months.</b>	This measure identifies HIV-infected persons, 2 years of age or older, taking antiretroviral medications that had at least one serum ALT or AST test in last 6 months of the report period.	© Ingenix, Inc.
# PSM-026-10 <b>Patient(s) with HIV infection taking antiretroviral medications that had a CBC in last 6 reported months.</b>	This measure identifies HIV-infected persons, 2 years of age or older, taking antiretroviral medications that had at least one CBC test in last 6 months of the report period.	© Ingenix, Inc.
# PSM-027-10 <b>Adult patient(s) with atrial fibrillation taking amiodarone that had serum ALT or AST test in last 12 reported months.</b> <i>* This measure will be considered for the Cardiovascular Endorsement Maintenance Project in Fall 2010.</i>	This measure identifies adults with atrial fibrillation, 18 years of age or older, taking amiodarone that had at least one serum ALT or AST test in last 12 months of the report period.	© Ingenix, Inc.

This information is for personal and noncommercial use only. You may not modify, reformat, copy, display, distribute, transmit, publish, license, create derivative works from, transfer or sell any information, products or services obtained from this document.

*National Voluntary Consensus for Patient Safety Measures 2010 Project*  
**Table of Candidate Consensus Standards - updated October 18, 2010**

Measure ID/ Title	Measure Description	Measure Steward
<p><b># PSM-028-10</b>  <b>Adult patient(s) taking a statin-containing medication or nicotinic acid that had an annual serum ALT or AST test.</b>  <i>* This measure will be considered for the Cardiovascular Endorsement Maintenance Project in Fall 2010.</i></p>	<p>This measure identifies adults, 18 years of age or older, taking a statin-containing medication or nicotinic acid that had at least one serum ALT or AST test in last 12 months of the report period.</p>	<p>© Ingenix, Inc.</p>
<p><b># PSM-029-10</b>  <b>Adult patient(s) taking warfarin that had three or more prothrombin time tests in last 6 reported months.</b>  <i>* This measure will be considered for the Cardiovascular Endorsement Maintenance Project in Fall 2010.</i></p>	<p>This measure identifies adults, 18 years of age or older, taking warfarin that had three or more prothrombin time tests in last 6 months of the report period.</p>	<p>© Ingenix, Inc.</p>
<p><b># PSM-030-10</b>  <b>Patient(s) with inflammatory bowel disease taking methotrexate, sulfasalazine, mercaptopurine, or azathioprine that had a CBC in last 3 reported months.</b></p>	<p>This measure identifies individuals with inflammatory bowel disease, 12 years of age or older, taking taking methotrexate, sulfasalazine, mercaptopurine, or azathioprine that had a CBC test in last 3 months of the report period.</p>	<p>© Ingenix, Inc.</p>
<p><b># PSM-031-10</b>  <b>Patient(s) with inflammatory bowel disease taking methotrexate that had a serum creatinine in last 6 reported months.</b></p>	<p>This measure identifies individuals with inflammatory bowel disease, 12 years of age or older, taking taking methotrexate that had a serum creatinine test in last 6 months of the report period.</p>	<p>© Ingenix, Inc.</p>

*National Voluntary Consensus for Patient Safety Measures 2010 Project*  
**Table of Candidate Consensus Standards - updated October 18, 2010**

Measure ID/ Title	Measure Description	Measure Steward
<b>Perinatal</b>		
<p><b># PSM-032-10</b>  <b>Adverse Outcome Index (AOI)</b>  <i>* This measure will be considered for the Perinatal Endorsement Maintenance Project in Spring 2011.</i></p>	<p>The rate and severity of adverse events in the obstetric population during their hospitalization</p> <ul style="list-style-type: none"> <li>o In-hospital maternal death.</li> <li>o In-hospital neonatal death</li> <li>o Uterine rupture</li> <li>o Unplanned maternal admission to the ICU</li> <li>o Birth Trauma</li> <li>o Maternal return to labor and delivery or the operating room</li> <li>o Unplanned admission to neonatal intensive care unit at term</li> <li>o Five-minute apgar &lt; 7</li> <li>o Maternal blood transfusion</li> <li>o Third or fourth degree laceration of the perineum</li> </ul>	<p>National Perinatal Information Center</p>
<p><b># PSM-033-10</b>  <b>Five minute APGAR less than 7</b>  <i>* This measure will be considered for the Perinatal Endorsement Maintenance Project in Spring 2011.</i></p>	<p>All live, inborn infants with birthweight greater than 2,499 who have a five-minute APGAR &lt; 7</p>	<p>National Perinatal Information Center</p>
<p><b># PSM-034-10</b>  <b>Birth Trauma</b>  <i>* This measure will be considered for the Perinatal Endorsement Maintenance Project in Spring 2011.</i></p>	<p>Injuries occurring during inborn labor only</p>	<p>National Perinatal Information Center</p>
<p><b># PSM-035-10</b>  <b>In-hospital Maternal Deaths</b>  <i>* This measure will be considered for the Perinatal Endorsement Maintenance Project in Spring 2011.</i></p>	<p>All pregnant women who die during the same hospital admission as their delivery</p>	<p>National Perinatal Information Center</p>

**This information is for personal and noncommercial use only. You may not modify, reformat, copy, display, distribute, transmit, publish, license, create derivative works from, transfer or sell any information, products or services obtained from this document.**

*National Voluntary Consensus for Patient Safety Measures 2010 Project*  
**Table of Candidate Consensus Standards - updated October 18, 2010**

Measure ID/ Title	Measure Description	Measure Steward
<b># PSM-036-10</b> <b>Unplanned maternal admission to the ICU</b> <i>* This measure will be considered for the Perinatal Endorsement Maintenance Project in Spring 2011.</i>	Any admission to the ICU or transfer to another hospital for admission to ICU during hospitalization in which the woman delivered a baby	National Perinatal Information Center
<b># PSM-037-10</b> <b>In-hospital Neonatal Death</b> <i>* This measure will be considered for the Perinatal Endorsement Maintenance Project in Spring 2011.</i>	Any newborn with discharge disposition of died within 7 days of birth (perinatal death), excluding cases with congenital anomalies, birth weight < 2500 grams or born outside the institution.	National Perinatal Information Center
<b># PSM-038-10</b> <b>Unplanned admission to neonatal intensive care unit at term</b> <i>* This measure will be considered for the Perinatal Endorsement Maintenance Project in Spring 2011.</i>	The rate of admission to the neonatal intensive care unit (NICU) (or transfer to another institution in hospitals that do not provide NICU care) for more than 24 hours of live inborns at => 37 weeks gestation and => 2500 grams	National Perinatal Information Center
<b># PSM-039-10</b> <b>Third or fourth degree laceration of the perineum</b> <i>* This measure will be considered for the Perinatal Endorsement Maintenance Project in Spring 2011.</i>	Number of women who suffer a 3rd or 4th degree laceration of the perineum during inborn vaginal delivery	National Perinatal Information Center
<b># PSM-040-10</b> <b>Maternal return to labor and delivery or the operating room</b> <i>* This measure will be considered for the Perinatal Endorsement Maintenance Project in Spring 2011.</i>	All women who return to the operating room or to labor and delivery during the delivery hospitalization for one of a set of specific indications	National Perinatal Information Center
<b># PSM-041-10</b> <b>Maternal blood transfusion</b> <i>* This measure will be considered for the Perinatal Endorsement Maintenance Project in Spring 2011.</i>	Number of women who receive a transfusion of blood or blood products during the hospital admission during which they deliver	National Perinatal Information Center

**This information is for personal and noncommercial use only. You may not modify, reformat, copy, display, distribute, transmit, publish, license, create derivative works from, transfer or sell any information, products or services obtained from this document.**

*National Voluntary Consensus for Patient Safety Measures 2010 Project*  
**Table of Candidate Consensus Standards - updated October 18, 2010**

<b>Measure ID/ Title</b>	<b>Measure Description</b>	<b>Measure Steward</b>
<b># PSM-042-10</b> <b>Uterine Rupture</b> <i>* This measure will be considered for the Perinatal Endorsement Maintenance Project in Spring 2011.</i>	Rupture of uterus during labor in the primary, first or second diagnosis code positions only	National Perinatal Information Center
<b>Other</b>		
<b># PSM-011-10</b> <b>Counseling about Epilepsy Specific Safety Issues</b>	Percentage of patients with diagnosis of epilepsy (of their caregiver(s)) counseled about context-specific safety issues, appropriate to the patient's age, seizure type(s) and frequency(ies), occupation and leisure activities, etc. (e.g. injury prevention, burns, appropriate driving restrictions or bathing) at least once a year.	© American Academy of Neurology
<b># PSM-012-10</b> <b>Querying about Falls (Parkinson's Disease Patients)</b>	Percentage of visits for patients with a diagnosis of Parkinson's disease where the patients (or caregiver(s), as appropriate) were queried about falls.	© American Academy of Neurology
<b># PSM-013-10</b> <b>Parkinson's Disease Related Safety Issues Counseling</b>	Percentage of patients with a diagnosis of Parkinson's disease (or caregiver(s), as appropriate) who were counseled about context-specific safety issues appropriate to the patient's stage of disease (eg injury prevention, medication management, or driving) at least annually.	© American Academy of Neurology
<b># PSM-014-10</b> <b>Colonoscopy Processing Personnel Instruction</b>	Percentage of all colonoscopy reprocessing personnel at Ambulatory Surgery Centers who receive current device-specific instructions at least annually to ensure proper colonoscopy reprocessing.	© AAAHC Institute for Quality Improvement
<b># PSM-015-10</b> <b>Colonoscopy Processing Currency</b>	Whether or not Ambulatory Surgery Centers performing colonoscopies review current national device-specific reprocessing guidelines and manufacturers' recommendations for reprocessing colonoscopies at least annually (every 12 months), and revise their policies and procedures to incorporate any changes that have occurred.	© AAAHC Institute for Quality Improvement

**This information is for personal and noncommercial use only. You may not modify, reformat, copy, display, distribute, transmit, publish, license, create derivative works from, transfer or sell any information, products or services obtained from this document.**

*National Voluntary Consensus for Patient Safety Measures 2010 Project*  
**Table of Candidate Consensus Standards - updated October 18, 2010**

<b>Measure ID/ Title</b>	<b>Measure Description</b>	<b>Measure Steward</b>
<b># PSM-016-10</b> <b>Colonoscope Processing Competency</b>	Percentage of all colonoscopy reprocessing personnel at Ambulatory Surgery Centers who are documented to be competent at reprocessing colonoscopies on initial assignment and at least annually thereafter.	© AAAHC Institute for Quality Improvement
<b># PSM-043-10</b> <b>Participation in a Systematic National Dose Index Registry</b>	Participation in a multi-center, standardized data collection and feedback program that will establish national dose index benchmarks for designated examinations. The registry will eventually provide a comparison of practice or facility dose indices such as CTDIvol and DLP for specified examinations relative to national and regional benchmarks. Data is captured electronically from the images of CT examinations using Digital Imaging and Communications in Medicine (DICOM) standards and the Integrating the Healthcare Enterprise (IHE) Radiation Exposure Monitoring (REM) profile.	American College of Radiology
<b>#PSM-044-10</b> <b>Radiation Dose of Computed Tomography (CT)</b>	This measure has two components: Part A is an outcome measure; Part B is a process measure. Both would work together toward improving quality and allowing hospitals and imaging facilities to conduct ongoing quality improvement. Part A: Radiation dose associated with computed tomography (CT) examinations of the head, neck, chest, abdomen/pelvis, and lumbar spine obtained in children and adults. Part B: The proportion of CT examinations where a measure of dose is included in the final medical report.	Rebecca Smith-Bindman, University of California San Francisco